Powered by
ANN ARBOR — The pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR) told its investors this week that following a $200 million public stock sale in March, it “estimates that current …
ANN ARBOR — Esperion Theapeutics Inc. (Nasdaq: ESPR), the developer of a new class of cholesterol-fighting drugs, has announced the intention to sell $85 million of its stock in a …
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ: ESPR) reported more positive “top-lline” results from the lates study of the effectiveness and safety of its ETC-1002 cholesterol drug in a Phase …